Literature DB >> 21802293

Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.

Steve Wenglowsky1, Kateri A Ahrendt, Alex J Buckmelter, Bainian Feng, Susan L Gloor, Stefan Gradl, Jonas Grina, Joshua D Hansen, Ellen R Laird, Paul Lunghofer, Simon Mathieu, David Moreno, Brad Newhouse, Li Ren, Tyler Risom, Joachim Rudolph, Jeongbeob Seo, Hillary L Sturgis, Walter C Voegtli, Zhaoyang Wen.   

Abstract

Structure-activity relationships around a novel series of B-Raf(V600E) inhibitors are reported. The enzymatic and cellular potencies of inhibitors derived from two related hinge-binding groups were compared and3-methoxypyrazolopyridine proved to be superior. The 3-alkoxy group of lead B-Raf(V600E) inhibitor 1 was extended and minimally affected potency. The propyl sulfonamide tail of compound 1, which occupies the small lipophilic pocket formed by an outward shift of the αC-helix, was expanded to a series of arylsulfonamides. X-ray crystallography revealed that this lipophilic pocket unexpectedly enlarges to accommodate the bulkier aryl group.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21802293     DOI: 10.1016/j.bmcl.2011.06.097

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  Analysis of B-Raf[Formula: see text] inhibitors using 2D and 3D-QSAR, molecular docking and pharmacophore studies.

Authors:  Reza Aalizadeh; Eslam Pourbasheer; Mohammad Reza Ganjali
Journal:  Mol Divers       Date:  2015-08-15       Impact factor: 2.943

2.  In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database.

Authors:  Zi-jie Wang; Zhi-ning Wan; Xu-dong Chen; Chuan-fang Wu; Guo-long Gao; Rong Liu; Zheng Shi; Jin-ku Bao
Journal:  J Mol Model       Date:  2015-04-02       Impact factor: 1.810

3.  The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury.

Authors:  J-X Li; J-M Feng; Y Wang; X-H Li; X-X Chen; Y Su; Y-Y Shen; Y Chen; B Xiong; C-H Yang; J Ding; Z-H Miao
Journal:  Cell Death Dis       Date:  2014-06-05       Impact factor: 8.469

4.  Design and Synthesis of Hsp90 Inhibitors with B-Raf and PDHK1 Multi-Target Activity.

Authors:  Luca Pinzi; Francesca Foschi; Michael S Christodoulou; Daniele Passarella; Giulio Rastelli
Journal:  ChemistryOpen       Date:  2021-10-11       Impact factor: 2.630

Review 5.  Photoresponsive Small Molecule Inhibitors for the Remote Control of Enzyme Activity.

Authors:  Dóra Laczi; Mark D Johnstone; Cassandra L Fleming
Journal:  Chem Asian J       Date:  2022-04-21

Review 6.  Structure, Function, and Regulation of the SRMS Tyrosine Kinase.

Authors:  Chakia J McClendon; W Todd Miller
Journal:  Int J Mol Sci       Date:  2020-06-14       Impact factor: 5.923

7.  Structural Basis for PPARα Activation by 1H-pyrazolo-[3,4-b]pyridine Derivatives.

Authors:  Takuya Yoshida; Hiroya Oki; Michihiro Doi; Syohei Fukuda; Tomohiro Yuzuriha; Ryotaro Tabata; Kenji Ishimoto; Kazuki Kawahara; Tadayasu Ohkubo; Hiroyuki Miyachi; Takefumi Doi; Keisuke Tachibana
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

8.  Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.

Authors:  Adel A-H Abdel-Rahman; Amira K F Shaban; Ibrahim F Nassar; Dina S El-Kady; Nasser S M Ismail; Samy F Mahmoud; Hanem M Awad; Wael A El-Sayed
Journal:  Molecules       Date:  2021-06-26       Impact factor: 4.411

9.  Oxazinethione Derivatives as a Precursor to Pyrazolone and Pyrimidine Derivatives: Synthesis, Biological Activities, Molecular Modeling, ADME, and Molecular Dynamics Studies.

Authors:  Magda H Abdellattif; Mohd Shahbaaz; M M H Arief; Mostafa A Hussien
Journal:  Molecules       Date:  2021-09-09       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.